MTOR and colorectal carcinoma: We analysed the activity of metformin in three CRC cell lines, one with BRAF as driver mutation, the others with KRAS mutation, one of which is an isogenic p53 null form and found for the first time that the drug transiently inhibited their growth and mTOR pathway activation by means of AMPK-dependent and -independent mechanisms.